leisure time -WSS

leisure time

author：hotspot 2025-10-01 00:49:51 - browse：5151

Each COVID-19 vaccine vial from various companies is placed on individual rectangular backgrounds. Pfizer-BioNTech is positioned in the middle on a purple block adorned with two glitter star stickers, Moderna is on the top right on a red block, Janssen is on the bottom right on a blue block, and AstraZeneca is on the left on a red block. — Illustration: Christine Kao/STAT; Photos: Getty

It’s been four years since Covid-19 emerged, igniting a pandemic that killed millions of people and brought the world to its knees. A key factor in taming the pandemic was the creation of effective vaccines, which have saved millions of lives.

You’d think developing a successful vaccine would be an unmitigated win, from a financial perspective. And, indeed, for Pfizer and its partner BioNTech, as well as for Moderna — whose vaccines were the most widely used in the United States and much of the world — the revenues generated were absolutely staggering. But investors have shrugged at those sales as gains that will not be repeated.

Total sales of the Pfizer/BioNTech vaccine surpassed $80 billion, and more than 400 million doses of the shot and subsequent boosters have been administered in the U.S. alone. But the company’s stock price fell 32% over the past five years. Meanwhile, AstraZeneca, which told STAT it has not booked sales from its vaccine since last April and does not expect future sales, has seen its share price rise 64%. Merck, which saw its vaccine efforts fail twice, is up 56%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： How to address the problem of discarded donor organs

knowledge

WSS

Brain 'hot spot' may explain why African Americans feel greater pain

Biotech companies concerned about China biosecurity crackdown

Australia's humpback populations rebound raising hopes of marine scientists

New case study details death in closely watched Alzhiemer's trial

Doctor appointment wait times are getting worse

Clinical trials giant ICON acquires HumanFirst

Wikipedia

leisure time

focus

Hepatitis C has a cure — but many Americans still lack access to it

Why getting cancer drugs just got harder for rural patients

Alkermes shareholders re

Pfizer's Covid pill remains 89% effective in final analysis, company says

Malaria cases in Florida and Texas: Here’s what you need to know

Medical device lobby: We're tired of waiting on Medicare coverage

Alkermes shareholders re

In search for therapies for solid tumors, companies turn to claudin

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why is France rioting? What to know about the fatal police shooting of Nahel M

focus

Clinical trials giant ICON acquires HumanFirst

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Meta looks to target Twitter with a rival app called Threads

Listen: Biogen's messy board & Laronde's data problem

Grail is spending more than ever lobbying Congress

Grail is spending more than ever lobbying Congress

entertainment

knowledge

hotspot

entertainment